{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:11:15Z","timestamp":1781557875039,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["U54MD012530"],"award-info":[{"award-number":["U54MD012530"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.pcad.2021.06.006","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T07:53:33Z","timestamp":1627458813000},"page":"92-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management"],"prefix":"10.1016","volume":"66","author":[{"suffix":"II","given":"Larry R.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2021.06.006_bb0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2021.06.006_bb0010","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2021.06.006_bb0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2021.06.006_bb0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0025","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2021.06.006_bb0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2021.06.006_bb0035","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2021.06.006_bb0040","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2021.06.006_bb0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2021.06.006_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/ATVBAHA.116.308595","article-title":"Factor XII as a therapeutic target in thromboembolic and inflammatory diseases","volume":"37","author":"Nickel","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0055","first-page":"19","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pcad.2021.06.006_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195950","article-title":"Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban","volume":"13","author":"Lip","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pcad.2021.06.006_bb0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2014.07.002","article-title":"Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"168","author":"O'Brien","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2021.06.006_bb0070","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pcad.2021.06.006_bb0075","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJM200105103441901","article-title":"Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation","volume":"344","author":"Klein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2021.06.006_bb0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/hrt.82.5.547","article-title":"Left atrial appendage: structure, function, and role in thromboembolism","volume":"82","author":"Al-Saady","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2021.06.006_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005359","article-title":"Percutaneous left atrial appendage closure: current devices and clinical outcomes","volume":"10","author":"Asmarats","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.06.006_bb0090","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0095","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.pcad.2021.06.006_bb0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2021.06.006_bb0105","unstructured":"https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=281&ExpandComments=n&DocID=CAG-00445N&bc=gAAAAAgAAgAAAA%3d%3d&. Accessed on December 28, 1980."},{"key":"10.1016\/j.pcad.2021.06.006_bb0110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2021.06.006_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0120","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1093\/eurheartj\/ehv730","article-title":"Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry","volume":"37","author":"Boersma","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2021.06.006_bb0125","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry","volume":"123","author":"Reddy","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2021.06.006_bb0130","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jacc.2019.09.064","article-title":"Long-term safety and efficacy in continued access left atrial appendage closure registries","volume":"74","author":"Holmes","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0135","first-page":"700","article-title":"Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience","volume":"77","author":"Park","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.06.006_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15420\/icr.2015.10.2.109","article-title":"Real world outcomes of left atrial appendage occlusion","volume":"10","author":"Tzikas","year":"2015","journal-title":"Interv Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0145","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4244\/EIJ-D-17-00493","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical\/echocardiographic data from a global prospective observational study","volume":"13","author":"Landmesser","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2021.06.006_bb0150","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0155","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4244\/EIJY15M01_06","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug","volume":"11","author":"Tzikas","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2021.06.006_bb0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hrthm.2016.10.020","article-title":"Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device","volume":"14","author":"Enomoto","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2021.06.006_bb0165","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4244\/EIJ-D-17-00042","article-title":"Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry","volume":"13","author":"Bergmann","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2021.06.006_bb0170","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4244\/EIJ-D-16-00726","article-title":"Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy","volume":"12","author":"Korsholm","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2021.06.006_bb0175","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jacc.2018.01.076","article-title":"Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation","volume":"71","author":"Fauchier","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0180","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1161\/STROKEAHA.117.018825","article-title":"Cost-effectiveness of left atrial appendage closure with the WATCHMAN device compared with warfarin or non-vitamin K antagonist oral anticoagulants for secondary prevention in nonvalvular atrial fibrillation","volume":"49","author":"Reddy","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2021.06.006_bb0185","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.mayocp.2018.09.025","article-title":"Left atrial appendage occlusion for the unmet clinical needs of stroke prevention in nonvalvular atrial fibrillation","volume":"94","author":"Holmes","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2021.06.006_bb0190","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.jacc.2015.09.084","article-title":"Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure","volume":"66","author":"Reddy","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"18_Supplement","key":"10.1016\/j.pcad.2021.06.006_bb0195","doi-asserted-by":"crossref","first-page":"B80","DOI":"10.1016\/j.jacc.2017.09.259","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0200","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2017.03.007","article-title":"The assessment of the watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial","volume":"189","author":"Holmes","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2021.06.006_bb0205","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamacardio.2018.3945","article-title":"Association of race\/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation II","volume":"3","author":"Essien","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11239-014-1145-7","article-title":"Review of race\/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials","volume":"39","author":"Jackson","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.pcad.2021.06.006_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012125","article-title":"Racial disparities in the utilization and outcomes of structural heart disease interventions in the United States","volume":"8","author":"Alkhouli","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2021.06.006_bb0220","article-title":"Sex-stratified analysis of the safety of percutaneous left atrial appendage occlusion","author":"Osman","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.06.006_bb0225","first-page":"805","article-title":"Left atrial appendage occlusion in octogenarians: short-term and 1-year follow-up","volume":"83","author":"Gafoor","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.06.006_bb0230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.amjcard.2015.10.024","article-title":"Comparison of efficacy and safety of left atrial appendage occlusion in patients aged <75 to >\/= 75 Years","volume":"117","author":"Freixa","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0235","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jcin.2016.04.019","article-title":"Predictors of early (1-week) outcomes following left atrial appendage closure with amplatzer devices","volume":"9","author":"Koskinas","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.06.006_bb0240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2013.02.089","article-title":"Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy","volume":"62","author":"Urena","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijcard.2017.07.052","article-title":"Left atrial appendage closure using AMPLATZER devices: A large, multicenter, Italian registry","volume":"248","author":"Berti","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2021.06.006_bb0250","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/heartjnl-2014-306332","article-title":"Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure","volume":"101","author":"Lopez Minguez","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2021.06.006_bb0255","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2021.06.006_bb0260","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jcin.2015.07.040","article-title":"Percutaneous left atrial appendage closure with the watchman device: long-term results up to 5 years","volume":"8","author":"Wiebe","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2021.06.006_bb0265","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/jce.13168","article-title":"Early canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure","volume":"28","author":"Saw","year":"2017","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062021000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062021000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:17:48Z","timestamp":1758500268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062021000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":53,"alternative-id":["S0033062021000578"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2021.06.006","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2021.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}